Skip to main content

Marketed Products

Two innovative therapies utilizing Kala’s proprietary AMPPLIFY® Drug Delivery Technology to address medical needs for front of the eye

EYSUVIS™ (loteprednol etabonate ophthalmic suspension) 0.25%

First and only prescription therapy specifically for the short-term management
of the signs and symptoms of dry eye disease

Inveltys (loteprednol etabonate ophthalmic suspension) 1% THERE IS NO GENERIC EQUIVALENT

First and only BID corticosteroid indicated for the treatment of post-operative ocular inflammation and pain

Internal Pipeline

Proprietary NCE development programs
targeted to address
front and back
of the eye diseases

  Tyrosine Kinase Inhibitor
Retinal diseases, including wet AMD, DME, and RVO
Surface Targeting Steroid (STS)
Corneal surface diseases
Selective Glucocorticoid Receptor Modulator (SEGRM)
Retinal diseases, including wet AMD, DME, and RVO; corneal surface diseases
Discovery
Lead Optimization
Candidate Selection
Formulation Development
IND-
Enabling Studies
Clinical Studies
Discovery Lead
Optimization
Candidate Selection Formulation Development IND-
Enabling Studies
Clinical Studies
Tyrosine Kinase Inhibitor
Retinal diseases, including wet AMD, DME, and RVO
Surface Targeting Steroid (STS)
Corneal surface diseases
Selective Glucocorticoid
Receptor Modulator (SEGRM)
Retinal diseases, including wet AMD, DME, and RVO;
corneal surface diseases

Please review our Privacy Statement. This website uses cookies. By using our website without changing your cookie settings you agree to our use of cookies as described in our Privacy Statement.